Global Innovative Platforms Reports Increased Operating Losses and Positive Shareholders' Equity

Global Innovative Platforms Inc. reported its financial results for the three and nine months ended June 30, 2025, revealing a significant increase in operating losses compared to the previous fiscal period. The company did not generate any revenue during these periods, maintaining a net loss of $211,818 for the three months and $483,635 for the nine months, compared to losses of $6,360 and $59,715, respectively, in the same periods of 2024. The increase in losses is attributed to heightened general and administrative expenses, which rose to $211,818 for the three months and $483,635 for the nine months, up from $6,360 and $59,715 in the prior year.

The company's balance sheet showed a substantial improvement in total assets, which increased to $209,160 as of June 30, 2025, compared to $15 as of September 30, 2024. This growth was primarily driven by an increase in cash and cash equivalents, which rose to $198,137 from $15. Shareholders' equity also turned positive, reaching $181,337, a significant recovery from a deficit of $33,138 in the previous fiscal year. The total liabilities decreased to $27,823 from $33,153, reflecting a reduction in loan payables and accounts payable.

Strategically, Global Innovative Platforms has made notable advancements, including the acquisition of a VOCAM Plus unit from Defiant Technologies for $55,115, which is expected to enhance its diagnostic capabilities. The company has also expanded its team, appointing Roger Hayes as VP of Business Development and formalizing agreements with key personnel to drive research initiatives. Additionally, the company launched a study with TRS Labs to explore early heartworm detection, which could lead to future revenue opportunities.

Operationally, the company has engaged in various initiatives to bolster its market presence. It has collected over 100 dog breath samples for research purposes and is in discussions with a global animal wellness company for a contract-driven project that aims to generate revenue. The company has also entered into a non-disclosure agreement with Defiant Technologies to explore licensing opportunities in the human health sector. As of June 30, 2025, the company had 42,181,241 shares outstanding, an increase from 33,745,491 shares in the previous year, indicating a potential increase in investor interest.

Looking ahead, Global Innovative Platforms acknowledges the need for substantial additional capital to support its operations and growth initiatives. The company plans to seek equity and debt financing to meet its ongoing expenses and pursue opportunities for growth. However, there is no assurance that it will be able to secure the necessary funding, which raises concerns about its ability to continue as a going concern. The company’s management has indicated that it will continue to monitor its financial position closely and take steps to address its operational and financial challenges.